Targeting PRMT5 in Adult T-Cell Leukemia/Lymphoma: Opportunities and Challenges

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy linked to human T-cell leukemia virus type 1 (HTLV-1).
• Current ATLL treatments show limited durability, necessitating novel therapeutic strategies.
• Protein arginine methyltransferase 5 (PRMT5) is implicated in cancer development and is overexpressed in various tumors.

Purpose of the Study:

• To review the role of PRMT5 in cancer biology.
• To summarize preclinical evidence supporting PRMT5 as a therapeutic target in ATLL.
• To discuss challenges and emerging strategies for clinical translation of PRMT5 inhibition in ATLL.

Main Methods:

• Literature review of PRMT5 biology and its role in cancer.
• Analysis of preclinical studies investigating PRMT5 inhibition in HTLV-1-infected T cells.
• Discussion of current challenges and future directions for PRMT5-targeted therapies in ATLL.

Main Results:

• PRMT5 expression is elevated in HTLV-1-associated T-cell transformation.
• Pharmacologic inhibition of PRMT5 selectively reduces the survival and transformation of HTLV-1-infected T cells in vitro and in vivo.
• PRMT5 plays a role in regulating key cellular processes, including transcription and DNA damage response.

Conclusions:

• PRMT5 is a viable therapeutic target for ATLL.
• Targeting PRMT5 offers a mechanism-based approach to combat ATLL.
• Combination therapies and selective PRMT5 inhibitors may enhance clinical efficacy for ATLL patients.